AS has poor outcomes unless treated. Transcatheter aortic valve replacement (TAVR) numbers are growing fast. Amyloidosis is caused by the deposition of abnormally folded protein resulting in progressive organ dysfunction. Wild-type transthyretin amyloid (wtATTR) affects the heart, causing a restrictive cardiomyopathy-deposits can be found in up to 25% of individuals >85 years of age at autopsy (1, 2 We conducted a pre-specified futility interim analysis of the ATTRact-AS study (NCT03029026), which seeks the prevalence and impact of occult Three DPD-positive patients had a plasma cell dyscrasia, but after review at the NAC, AL amyloidosis was felt unlikely in all cases. All DPD-positive patients genotyped so far were wild type (n ¼ 5).
There was 1 periprocedural permanent pacemaker, 1 implantable cardiac defibrillator, and 1 spinal cord infarction in the DPD-positive cohort. There were also 2 deaths pre-TAVR in the DPD-positive cohort (14%).
These findings support the work of Castaño et al.
(3) that approximately 1 in 7 patients currently undergoing TAVR have occult cardiac amyloidosis-a higher prevalence than surgical aortic valve replacement cohorts (4). We note that 2 DPD-positive patients died before TAVR, raising the possibility that these patients represent a higher-risk subgroup even pre-procedure. Furthermore, wtATTR typically affects males more, but here the male and female prevalence of amyloid were similar (16% prevalence in men, 12% in women), as found in the heart failure with preserved ejection fraction population (5).
Finally, the amyloid burden was skewed: rather than a pyramidal distribution with DPD grade 1>2>3, DPD grade 2 was dominant. This may support proposals of an interaction between AS and amyloid.
The confirmation of such a high prevalence of occult amyloid in TAVR patients has implications.
Cardiac amyloid profoundly alters the myocardium and is likely to affect clinical presentation and 
